Myasthenia Gravis Treatment Denied by Insurance? How to Appeal

Myasthenia gravis (MG) is a rare autoimmune neuromuscular disease causing fluctuating muscle weakness and fatigability. Treatment has advanced dramatically — from pyridostigmine and steroids to complement inhibitors (Soliris, Ultomiris) and neonatal Fc receptor (FcRn) blockers (Vyvgart, Rystiggo). Insurance denials are common at every level of treatment, from initial diagnostic testing to the newest biologic therapies. This guide explains how to appeal effectively.

Why Insurers Deny MG Treatment

Diagnostic testing denied — Acetylcholine receptor (AChR) antibody testing, anti-MuSK antibody testing, single-fiber EMG, repetitive nerve stimulation, and tensilon (edrophonium) testing may each face Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements or denial as "not medically necessary."

Thymectomy authorization denied — The MGTX trial (2016, NEJM) established that thymectomy improves outcomes in generalized MG patients aged 18–65 who are AChR antibody positive, even without thymoma. Despite this landmark evidence, thymectomy is still denied by some insurers as "not medically necessary" for non-thymomatous MG.

Pyridostigmine (Mestinon) denied — Pyridostigmine, the foundational symptomatic treatment for MG, is an old, inexpensive drug that is rarely denied outright but may face formulary restrictions or quantity limits.

Eculizumab (Soliris) denied — Soliris is FDA-approved for refractory generalized AChR+ MG. Prior authorization criteria are strict: confirmed AChR antibody positivity, generalized MG (not purely ocular), documented failure of at least two immunosuppressive therapies (such as pyridostigmine + prednisone + azathioprine or mycophenolate), and high disease activity score. Soliris costs $700,000+ per year, making insurer resistance intense.

Ravulizumab (Ultomiris) denied — Ravulizumab is a longer-acting C5 complement inhibitor approved for MG with similar prior authorization requirements to Soliris. Monthly vs. biweekly dosing is the key practical difference.

Efgartigimod (Vyvgart) denied — Vyvgart is an FcRn inhibitor approved for AChR+ generalized MG. It lowers IgG antibodies by blocking FcRn recycling. Prior auth requirements include AChR antibody confirmation, generalized MG, and prior immunosuppressive therapy failure.

IVIG and plasma exchange denied — IVIG and plasmapheresis are used for MG exacerbations and crisis management. Denial of these treatments for acute worsening is particularly dangerous.

Clinical Frameworks Supporting Your Appeal

International Consensus Guidance for MG (2016, Myasthenia Gravis Foundation of America) — The MGFA International Consensus Guidance provides comprehensive treatment recommendations used as the global clinical standard. Treatment recommendations are stratified by MG class (ocular vs. generalized), antibody status, and disease severity.

MGTX Trial — The MGTX randomized controlled trial demonstrated that thymectomy in non-thymomatous, AChR antibody-positive generalized MG resulted in significantly fewer hospitalizations, lower steroid doses, and better clinical outcomes over 3 years compared to immunotherapy alone. This is Class I evidence supporting thymectomy. If your thymectomy was denied, cite MGTX directly.

MG-ADL and QMGS Scores — The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale and Quantitative Myasthenia Gravis Score (QMGS) are validated instruments documenting disease severity. A QMGS above 10 or MG-ADL above 6 indicates moderate-to-severe disease. Include these scores in your appeal documentation.

ADAPT Trial (Vyvgart) — The ADAPT trial demonstrated significant improvement in MG-ADL scores with efgartigimod vs. placebo in AChR+ generalized MG patients. Results were particularly strong in AChR+ subgroup. Submit AChR antibody result and ADAPT trial data when appealing Vyvgart denials.

REGAIN Trial (Soliris/Eculizumab) — The REGAIN trial established efficacy of eculizumab in refractory AChR+ MG. The trial enrolled patients who had failed ≥2 immunosuppressive therapies. Document failed therapies to mirror REGAIN enrollment criteria.

Meningococcal Vaccination Requirement — Eculizumab and ravulizumab block complement and increase meningococcal infection risk. Before approval, insurers require documentation of meningococcal vaccination (MenACWY and MenB). Confirm vaccination status is documented in the medical record to avoid administrative denial.

Step-by-Step Appeal Strategy

Step 1: Document the diagnosis with objective evidence. Include AChR antibody result (quantitative level, not just positive/negative), anti-MuSK if AChR negative, single-fiber EMG or repetitive nerve stimulation results, and clinical history documenting fluctuating, fatigable weakness.

Step 2: Classify disease severity. Submit MGFA clinical classification (Class I = ocular only; Class II–V = generalized) and current MG-ADL and/or QMGS scores.

Step 3: Document failed prior therapies. For Soliris, Ultomiris, or Vyvgart appeals, list each immunosuppressive therapy tried: corticosteroids (dose, duration, response), azathioprine, mycophenolate mofetil, tacrolimus, and any prior IVIG or plasma exchange courses. Document why each was stopped (toxicity, inadequate response) and what the clinical status was at the time of discontinuation.

Step 4: For thymectomy appeals. Document: age (18–65 per MGTX criteria), AChR antibody positivity, generalized (not purely ocular) MG, and current QMGS/MG-ADL. Include chest CT showing no thymoma but presence of thymic tissue. Cite MGTX trial results directly.

Step 5: For crisis/exacerbation IVIG/PE denials. Document the severity of the acute worsening — difficulty swallowing, respiratory compromise, hospitalization. IVIG and plasmapheresis for MG crisis are established standard of care and should not be denied for acute, life-threatening exacerbations.

Step 6: Request expedited review for active worsening. Myasthenic crisis is a medical emergency. If treatment is being denied while a patient is actively deteriorating, file an expedited appeal and document the clinical urgency.

Fight Back With ClaimBack

Myasthenia gravis is unpredictable and potentially life-threatening. Delays in accessing advanced therapies increase the risk of myasthenic crisis. ClaimBack helps you compile your antibody testing, disease activity scores, failed therapy documentation, and clinical trial data into a complete, targeted appeal.

Start your myasthenia gravis appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals